Market Overview

UPDATE: Wedbush Maintains Raptor Pharmaceutical at Outperform as FDA Pushes Back PDUFA Date

Related RPTP
Wedbush Previews Raptor Pharmaceutical Q4, Lowers Sales Estimates
JMP Securities Weighs In On Q4 Earnings For Raptor Pharmaceutical
Raptor Pharmaceuticals Has High-Reward Catalysts (Seeking Alpha)

Wedbush reiterated its Outperform rating and $10 price target on Raptor Pharmaceutical (NASDAQ: RPTP).

Wedbush commented, "RPTP recently announced that the FDA has pushed PROCYSBI (RP103) PDUFA date to April 30 from January 30. Importantly, FDA is not requesting additional studies or information. RP103 is also under review by the EMA, with potential approval anticipated mid-13. … Our launch expectations remain unchanged, and following a recent debt deal, the company has $50 million in cash, which is estimated to be sufficient into profitability."

Raptor Pharmaceutical closed at $5.51 on Friday.

Latest Ratings for RPTP

Feb 2015Leerink SwannMaintainsOutperform
Oct 2014OppenheimerInitiates Coverage onMarket Perform
May 2014Leerink SwannMaintainsOutperform

View More Analyst Ratings for RPTP
View the Latest Analyst Ratings

Posted-In: WedbushAnalyst Color Reiteration Intraday Update Analyst Ratings


Related Articles (RPTP)

Around the Web, We're Loving...